NCT06308588 2026-04-14
Phase I/II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
M.D. Anderson Cancer Center
Novartis
Novartis
Korean Society of Hematology
Augusta University
Novartis
Novartis